French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...

(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least ...

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

China’s National Medical Products Administration (NMPA) has approved French Pharma major Sanofi’s Sarclisa (isatuximab), an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) ...

"Additionally, its unique anti-CD38 region avoids competition with daratumumab, a commonly used monoclonal antibody in multiple myeloma treatment." The ongoing, first-in-human phase I trial ...

(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least ...